Compare VABK & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VABK | MDWD |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.3M | 212.1M |
| IPO Year | 2013 | 2013 |
| Metric | VABK | MDWD |
|---|---|---|
| Price | $42.60 | $16.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $36.00 |
| AVG Volume (30 Days) | 4.4K | ★ 51.0K |
| Earning Date | 04-23-2026 | 05-20-2026 |
| Dividend Yield | ★ 3.39% | N/A |
| EPS Growth | ★ 12.70 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $48.92 |
| Revenue Next Year | N/A | $35.04 |
| P/E Ratio | $43.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $36.37 | $14.90 |
| 52 Week High | $48.58 | $22.51 |
| Indicator | VABK | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 47.69 |
| Support Level | $38.18 | $16.26 |
| Resistance Level | $43.98 | $18.38 |
| Average True Range (ATR) | 1.09 | 0.51 |
| MACD | -0.23 | -0.03 |
| Stochastic Oscillator | 15.79 | 35.99 |
Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.